|
|
Article: Strategic Partnerships Advantageous to Start-up Biotech Companies.
- Article from:
- Business Wire
- Article date:
- January 26, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
PALO ALTO, Calif.--(BUSINESS WIRE)--Jan. 26, 2004
Lack of competitive marketing skills and experience in conducting clinical trials is a major drawback of research-based start-up biotech companies. Strategic partnering by small biotech companies with larger participants to aid commercialization of its proprietary biotech products can help overcome this problem.
New analysis from Frost & Sullivan (http://www.biotech.frost.com), U.S. Biotechnology Pipeline Analysis, reveals that revenue from products in the pipeline totaled $0.21 billion in 2003 and is projected to reach $13.79 billion by 2009.
If ...